scholarly journals Complete Tumor Cell Necrosis

2020 ◽  
Author(s):  
2009 ◽  
Vol 46 (14) ◽  
pp. 2831-2832
Author(s):  
Lili Liu ◽  
Zhuoya Li ◽  
Michael Kirschfink

2007 ◽  
Vol 62 (3) ◽  
pp. 491-498 ◽  
Author(s):  
Victor Adler ◽  
Wilbur Bowne ◽  
Ikram Kamran ◽  
Josef Michl ◽  
Fred K. Friedman ◽  
...  

PLoS ONE ◽  
2011 ◽  
Vol 6 (8) ◽  
pp. e23270 ◽  
Author(s):  
Jiemiao Hu ◽  
Xinli Liu ◽  
Dennis Hughes ◽  
Francisco J. Esteva ◽  
Bolin Liu ◽  
...  

2010 ◽  
Vol 24 (S1) ◽  
Author(s):  
Cuiping Zhao ◽  
Yunyi Hong ◽  
Jin Han ◽  
Weiliang Xia ◽  
Weihai Ying

2019 ◽  
Vol 181 (2) ◽  
pp. K21-K27 ◽  
Author(s):  
Eva C Coopmans ◽  
Sebastiaan W F van Meyel ◽  
Kay J Pieterman ◽  
Jolique A van Ipenburg ◽  
Leo J Hofland ◽  
...  

Prolactinomas are the most commonly encountered pituitary adenomas in the clinical setting. While most can be controlled by dopamine agonists, a subset of prolactinomas are dopamine-resistant and very aggressive. In such tumors, the treatment of choice is neurosurgery and radiotherapy, with or without temozolomide. Here, we report a patient with an highly aggressive, dopamine-resistant prolactinoma, who only achieved biochemical and tumor control during pasireotide long-acting release (PAS-LAR) therapy, a second-generation somatostatin receptor ligand (SRL). Interestingly, cystic degeneration, tumor cell necrosis or both was observed after PAS-LAR administration suggesting an antitumor effect. This case shows that PAS-LAR therapy holds clinical potential in selective aggressive, dopamine-resistant prolactinomas that express somatostatin (SST) receptor subtype 5 and appears to be a potential new treatment option before starting temozolomide. In addition, PAS-LAR therapy may induce cystic degeneration, tumor cell necrosis or both in prolactinomas.


Sign in / Sign up

Export Citation Format

Share Document